Table 3.
Relative Expression and Content of PTEN, AKT, GSK-3ß, PDK1, c-RAF, m-TOR, 70 S6 Kinase and 4E-BP1 in Disseminated Cancer Tissues of Kidney before (Untreated Group) and after Pazopanib Targeted Therapy (Pazopanib Treated Group)
| Parameter, Relative units | n | Untreated group | Pazopanib treated group | Parameter, % | Untreated group | Pazopanib treated group |
|---|---|---|---|---|---|---|
| AKT/m-TOR signaling pathway components expression | AKT/m-TOR signaling pathway components content | |||||
| PTEN | 33 | 1.0±0.5 | 2.0±0.5 | phospho -PTEN | 96.8 (64.9-112.45) | 56.14 (55.2-57.0)* |
| AKT | 33 | 34.7±23.7 | 105.0±41.6* | AKT (pan) | 129.7 (103.8-223.75) | 212.7 (175.4-250.1) |
| phospho -AKT (308) | 105.1 (73.1-156.6) | 70.3 (55.9-84.7)* | ||||
| phospho -AKT (473) | 101.95 (72.5-137.7) | 118.9 (105.2-132.6) | ||||
| GSK-3-beta | 33 | 22.7±8.1 | 46.5±24.6* | phospho -GSK-3-b | 144.8 (101.7-232.5) | 199.8 (147.5-252.1) |
| PDK1 | 33 | 21.1±10.1 | 74.5±34.5 | phospho -PDK1 | 129.5 (86.9-162.4) | 144.3 (132.6-156.0) |
| c-RAF | 33 | 35.2±9.9 | 52.6±36.6 | phospho -c-Raf | 145.9 (93.6-240.7) | 155.6 (93.6-240.7) |
| m-TOR and its substrates expression | m-TOR and its substrates expression content | |||||
| m-TOR | 33 | 33.8±15.5 | 25.1±10.2 | m-TOR | 157.3 (75.35-218.0) | 133.9 (129.4-138.4) |
| 70 S6 kinase | 33 | 32.1±14.2 | 13.1±12.7 | phospho -mTOR (Ser2448) | 116.7 (79.5-173.5) | 179.0 (160.4-197.7) |
| phospho-p70 S6 (S371) | 90.35 (44.7-117.8) | 175.2 (101.9-248.5)* | ||||
| phospho-p70 S6 kinase (T389) | 109.7 (83.4-155.5) | 101.2 (93.8-108.6) | ||||
| 4E-BP1 | 33 | 18.4±7.9 | 49.8±23.7 | phospho-4E-BP1 | 109.7 (83.4-155.5) | 101.2 (93.8-108.6) |
*
- Level of significance compared to the patients untreated with pazopanib; p<0.05;